LimmaTech Biologics is a biotech company that develops vaccines to prevent microbial infections and address antimicrobial resistance.
LimmaTech Biologics has raised $6.5M in total funding. The most recent round was Grant. The last funding was announced in February 2025.
LimmaTech Biologics's investors include AXA Investment Managers, Adjuvant Capital, CARB-X, Repair Impact Fund, Tenmile.
LimmaTech Biologics is headquartered in Schlieren, Switzerland.
LimmaTech Biologics is a biotech company that develops vaccines to prevent microbial infections and address antimicrobial resistance.
LimmaTech Biologics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LimmaTech Biologics — Funding & Investors." VCBacked, February 17, 2025, https://www.vcbacked.co/company/limmatech-biologics. Accessed September 30, 2026.
VCBacked. (2025). LimmaTech Biologics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/limmatech-biologics
{{cite web |title=LimmaTech Biologics — Funding & Investors |url=https://www.vcbacked.co/company/limmatech-biologics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated